The FDA released a 53-page analysis from Pfizer in which the drugmaker outlines data it says supports the authorization of a third dose of its COVID-19 vaccine.
Pfizer found five side effects to be most common after the third dose in its trial, which included 289 participants ages 18 to 55. They are listed below, along with the percentage of participants who reported experiencing these side effects:
- Injection site pain: 83 percent
- Fatigue: 63.7 percent
- Headache: 48.4 percent
- Muscle and joint pain: 39.1 percent
- Chills: 29.1 percent
